Assessing Cardiovascular Risk in Women Considering Menopausal Hormone Therapy

  • Duration: 58 Minutes

Price: $69.00

Member Price: $59.00

Rating: Member Average

This webcast originally aired as a live webinar sponsored by AACC on March 11, 2014. When the results of the Women's Health Initiative (WHI) Estrogen Plus Progestin study demonstrated that menopausal hormone therapy (HT) did not decrease cardiovascular risk as expected and was associated with an increased risk of developing breast cancer, clinicians stopped prescribing it routinely to women undergoing menopause. However, HT is still prescribed to manage the symptoms of menopause, and recent studies have shown that many newly menopausal women have a favorable benefits:risk profile on HT. The key is to apply risk-stratification strategies and personalization of care to identify appropriate candidates for treatment and to avoid HT in women likely to have adverse events. View this program and learn what recent data are telling us about the relationship between HT and CVD risk; which women can benefit most from HT and which women should avoid HT; what role labs can play in helping clinicians assess CVD risk in women considering HT; and why a personalized approach to the prediction of risk for CVD and other events while on HT makes sense.